Biological psychiatry global open science · 2026
Selective mGlu1 Receptor Activation Restores Cortical Inhibitory Tone and Improves Cognitive Performance in a Subchronic Phencyclidine NMDA Hypofunction Model.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luessen Deborah J, Gallinger Isabel M, Wolfe Brenna, Meadows Mac J, Leonard Michael Z, Freitas Geanne A, Lindsley Craig W, Calipari Erin S, Niswender Colleen M, Conn P Jeffrey
Аннотация
BACKGROUND: Deficits in prefrontal cortex (PFC) inhibitory transmission are thought to underlie the cognitive symptoms of schizophrenia that remain untreated by current pharmacotherapies. The metabotropic glutamate 1 (mGlu1) receptor, a subtype of the mGlu receptor family, is a promising therapeutic target because its activation enhances inhibitory transmission in the PFC through the excitation of somatostatin-expressing GABAergic (gamma-aminobutyric acidergic) interneurons (SST-INs).
METHODS: We used a subchronic phencyclidine (PCP) NMDA receptor antagonist mouse model, mGlu1 positive allosteric modulators (PAMs), and mice with selective deletion of mGlu1 receptors from SST-INs to examine the cell type-specific role of mGlu1 signaling in cortical inhibition and cognition. We used ex vivo whole-cell patch-clamp electrophysiology to assess inhibitory transmission in the PFC, and cognitive performance was evaluated using tests of working memory and novel object recognition.
RESULTS: Subchronic PCP treatment impaired inhibitory synaptic transmission in the PFC, particularly onto layer V pyramidal neurons projecting to the nucleus accumbens. Pharmacological activation of mGlu1 restored inhibitory drive and reversed PCP-induced deficits in working memory and novel object recognition. Importantly, selective deletion of mGlu1 receptors from SST-INs abolished the ability of mGlu1 activation to restore cortical inhibition and cognitive function, demonstrating that these receptors are required for the therapeutic effects of mGlu1 PAMs.
CONCLUSIONS: These findings identify SST-IN-expressed mGlu1 receptors as critical regulators of prefrontal cortical inhibition and cognition. Positive allosteric modulation of mGlu1 represents a promising therapeutic strategy for treating cognitive deficits associated with schizophrenia by restoring inhibitory circuit function.
METHODS: We used a subchronic phencyclidine (PCP) NMDA receptor antagonist mouse model, mGlu1 positive allosteric modulators (PAMs), and mice with selective deletion of mGlu1 receptors from SST-INs to examine the cell type-specific role of mGlu1 signaling in cortical inhibition and cognition. We used ex vivo whole-cell patch-clamp electrophysiology to assess inhibitory transmission in the PFC, and cognitive performance was evaluated using tests of working memory and novel object recognition.
RESULTS: Subchronic PCP treatment impaired inhibitory synaptic transmission in the PFC, particularly onto layer V pyramidal neurons projecting to the nucleus accumbens. Pharmacological activation of mGlu1 restored inhibitory drive and reversed PCP-induced deficits in working memory and novel object recognition. Importantly, selective deletion of mGlu1 receptors from SST-INs abolished the ability of mGlu1 activation to restore cortical inhibition and cognitive function, demonstrating that these receptors are required for the therapeutic effects of mGlu1 PAMs.
CONCLUSIONS: These findings identify SST-IN-expressed mGlu1 receptors as critical regulators of prefrontal cortical inhibition and cognition. Positive allosteric modulation of mGlu1 represents a promising therapeutic strategy for treating cognitive deficits associated with schizophrenia by restoring inhibitory circuit function.